The Symaptics MFN Hub
MFN drug pricing.
Policy and global impact.
Your guide to US most-favored-nation drug pricing. Compare the programmes, follow manufacturer agreements, and understand what they mean for global pricing strategy.
US policy checked View sources
Latest developments & recent history
What has changed?
GLOBE litigation
PhRMA challenges the GLOBE final rule
PhRMA filed suit in federal court in Washington, DC, arguing that CMS exceeded its authority and asking the court to set aside GLOBE. The challenge is pending; no order pausing the model was identified in public sources checked on 10 October. CMS still lists a 1 January 2027 model start and 1 April performance start.
Medicare
GUARD final rule still under review
The Part D model’s final rule has been under OMB review since 15 June and had not been published by 3 October. CMS still describes GUARD as a proposal, so its proposed 1 January 2027 start is not yet confirmed.
GENEROUS · Reported update
All 50 states reported to have signed
Inside Health Policy reported that CMS said all 50 states had signed final participation agreements following the 30 September deadline. CMS’s public model page still carries the earlier application update. Signing does not establish that every product-level rebate arrangement is operational.
Medicare
GLOBE final rule released
CMS finalised GLOBE as a mandatory Part B model, publishing the rule on 2 October. The model begins on 1 January 2027 and its first performance year on 1 April 2027. The 19-country basket is unchanged, CMS intends to waive GENEROUS participants, and the scope and estimated savings are narrower than proposed.
Tariff milestone
Pharmaceutical tariffs reached remaining manufacturers
The April proclamation now covers companies outside Annex III. Patented products face 100%, or 15% from the EU, Japan, Korea and Switzerland; an HHS MFN agreement plus an approved onshoring plan gives zero until January 2029. Commerce has zero-rated specified specialty products, such as orphan-only drugs, from qualifying jurisdictions.
Agreement disclosures
Pfizer and Lilly MFN agreement terms released
Redacted agreements published by Public Citizen reveal Lilly’s separate GLP-1 arrangements and Pfizer’s GENEROUS and overseas revenue-sharing terms. Important coverage and pricing details remain undisclosed, reinforcing the need to assess each agreement individually.
GENEROUS
40 states and Puerto Rico had signed
All 50 states, DC and Puerto Rico had applied; 40 states and Puerto Rico had signed participation agreements. CMS gave the remaining states until 30 September to sign. Signed participation does not confirm that every arrangement was operational.
Agreements
Announced MFN deals reached 26 manufacturers
Nine additional manufacturers joined the announced framework. Product coverage, implementation and duration still needed to be read against each company’s disclosed terms.
Tariff milestone
First pharmaceutical tariff phase began
The April proclamation set 31 July for the companies listed in Annex III and 29 September for others. Qualifying MFN and US investment agreements provide a route to zero tariff treatment; exposure depends on the company, product and origin.
GLP-1 access
Medicare GLP-1 Bridge began
The demonstration opened access to selected GLP-1 medicines for eligible Part D beneficiaries, with a $50 copay. It operates outside the normal Part D benefit and payment flow, separately from the proposed GUARD model.
Research context
HHS examined who funds drug innovation
An HHS analysis compared OECD countries’ shares of revenues from innovative medicines using 2020–2025 data. It adds context to the international burden-sharing debate behind MFN; it does not introduce a new pricing rule or demonstrate realised MFN savings.
June to October 2026. Each summary reflects the event or status check on its stated date.
Start here
Four MFN pathways. Different implications.
MFN connects US drug pricing to international prices. Who participates, which products are covered and how the benchmark is applied vary by pathway.
GENEROUS
Internationally informed supplemental rebates for participating manufacturers and state Medicaid programmes.
- Participation
- Voluntary
- Reference basket
- 8 countries
- Model period
- 2026–2030
GLOBE
An international benchmark within the Part B inflation-rebate framework for eligible drugs administered in clinical settings. PhRMA’s legal challenge is pending.
- Participation
- Mandatory, in randomly selected areas
- Reference basket
- 19 countries
- Model start
- 1 January 2027
First performance year from 1 April 2027
GUARD
An international benchmark used to modify inflation rebates for eligible drugs covered under Medicare Part D.
- Participation
- Mandatory if implemented, in test regions
- Reference basket
- 19 countries, proposed
- Original proposed start
- 1 January 2027
Final rule pending
MFN agreements
Company-specific commitments covering Medicaid, selected direct-to-consumer offers and prospective pricing for new medicines.
- Participation
- Negotiated agreements
- Manufacturers
- 26 announced
- Duration & scope
- Company-specific
Explore the detail
Compare MFN programmes, countries and dates.
Compare two pathways
Choose any pair. Key differences stay visible on every screen.
GLOBE
GUARD
Policy status
Coverage
Participation
Mechanism
Reference basket
Pricing approach
Start / timing
Duration
Planning question
Overview only. Product eligibility, benchmark calculations and exclusions require the relevant model documentation or disclosed agreement terms. Primary sources ↓
Which countries are referenced?
Explore the two baskets, then choose a country to see its economic context and illustrative Medicare price adjustment.
GLOBE / GUARD · 19 reference countries
Hover for a quick view; press Escape to dismiss it. Select a country on the map or use the dropdown for its full profile.
How to read the country data
Economic figures: World Bank, 2024 (July 2026 release). Adjusters: the final GLOBE rule’s illustrative Table 5, which divides US GDP per person by the country’s, with a minimum of 1.000. It is not an exchange rate.
Country inclusion differs by pathway. Basket membership does not mean every product or price is covered. View sources ↓
Compare all 19 country profiles
| Country | GENEROUS | Real GDP (PPP) | GDP/person (PPP) | % of US | Adjuster |
|---|---|---|---|---|---|
| Australia | Outside basket | $1,961bn | $72,100 | 84% | 1.190 |
| Austria | Outside basket | $695bn | $75,800 | 88% | 1.161 |
| Belgium | Outside basket | $880bn | $74,200 | 86% | 1.167 |
| Canada | Included | $2,702bn | $65,500 | 76% | 1.328 |
| Czechia | Outside basket | $628bn | $57,600 | 67% | 1.498 |
| Denmark | Included | $484bn | $80,900 | 94% | 1.048 |
| France | Included | $4,286bn | $62,500 | 73% | 1.372 |
| Germany | Included | $6,177bn | $74,000 | 86% | 1.167 |
| Ireland | Outside basket | $760bn | $140,800 | 163% | 1.000* |
| Israel | Outside basket | $573bn | $57,300 | 66% | 1.500 |
| Italy | Included | $3,672bn | $62,300 | 72% | 1.384 |
| Japan | Included | $6,714bn | $54,200 | 63% | 1.648 |
| Netherlands | Outside basket | $1,533bn | $85,200 | 99% | 1.000* |
| Norway | Outside basket | $589bn | $105,700 | 123% | 1.000* |
| South Korea | Outside basket | $3,159bn | $61,100 | 71% | 1.406 |
| Spain | Outside basket | $2,836bn | $58,100 | 67% | 1.480 |
| Sweden | Outside basket | $753bn | $71,200 | 83% | 1.194 |
| Switzerland | Included | $878bn | $97,500 | 113% | 1.000* |
| United Kingdom | Included | $4,354bn | $62,800 | 73% | 1.383 |
All 19 countries are in the GLOBE/GUARD basket, final for GLOBE and proposed for GUARD. * The final rule’s table sets these adjusters at the 1.000 minimum. Adjusters are the final rule’s illustrative values, calculated from an earlier release of the same World Bank series, so they can differ slightly from a ratio of the GDP figures shown. The adjuster does not apply to every MFN pathway. CMS Table 5 ↗
Explore the MFN timeline
Follow GENEROUS, GLOBE and GUARD through reporting, performance and payment periods. Use the date control and filters to explore each model.
Open full window ↗Confirmed dates are distinguished from proposed and illustrative milestones. GLOBE follows the final rule; GUARD remains proposed. Payment and reconciliation examples depend on reporting, receipt or agreement terms. Changing the selected date does not change a model’s policy status.
Key dates at a glance
A quick reference to announcements, participation deadlines and model start dates, with links to the sources.
First manufacturer MFN agreement announced
Pfizer announcement begins the series of bilateral deals. Individual implementation dates vary.
GENEROUS model launches
The model launches; participation and implementation arrangements follow their own milestones.
Nine further deals bring the total to 26
The White House announces agreements with nine additional manufacturers.
40 states and Puerto Rico signed
CMS reports applications from all 50 states, DC and Puerto Rico, with 40 states and Puerto Rico already signed. Operational arrangements still need to be checked.
Remaining state participation agreements due
CMS gave the remaining states until this date to sign participation agreements. The subsequent participation report is listed below.
GLOBE final rule released
CMS finalised the Part B model. The rule was published on 2 October and takes effect on 30 November 2026.
All 50 states reported to have signed
Inside Health Policy reports that CMS says all 50 states signed final participation agreements. Product-level implementation remains a separate step.
PhRMA files GLOBE lawsuit
PhRMA asks the court to set aside the final rule. The filing itself does not change the scheduled model or performance dates.
GLOBE begins
The model opens with voluntary manufacturer submission of international net pricing data, ahead of the first performance year.
GUARD performance period would begin
The final rule has been under OMB review since 15 June and had not been published by 3 October 2026. This original proposed date is not a confirmed launch.
First GLOBE performance year begins
Five performance years run to 31 March 2032, with invoicing and reconciliation continuing to 31 March 2034.
Proposed dates are planning assumptions, not confirmation of implementation. Performance periods and later payment/reconciliation periods are different. Read the underlying sources ↓
Expert perspective
MFN policy and pricing analysis.
Selected reading from Symaptics. Articles reflect their publication date; use the status updates above for the current policy position.
GLOBE Final Rule: What Changed and Why It Matters for Global Pricing
What the final Part B rules mean for global pricing strategy, GENEROUS participation and exposure modelling.
The Art of the MFN Deal
The CEA’s savings analysis and the strategic choices behind voluntary manufacturer agreements.
GLOBE & GUARD: MFN comes to Medicare
How the proposed Part B and Part D models differ, and why the mechanics matter.
The End of Two Silos
Why US and international pricing decisions need to be assessed together.
GENEROUS: Medicaid’s MFN test
An introduction to the model’s reference basket, net-price benchmark and supplemental rebates.
The fine print in GLOBE & GUARD
A closer look at purchasing-power adjustments and benchmark design in the proposals.
Redefining ex-US success
How launch sequencing and portfolio decisions can reshape the global value equation.
MFN and the shift of risk
What a US pricing policy could mean for access and investment decisions outside the US.
Introducing SyMAP 2.0
Connected pricing, MFN and revenue scenarios, with voluntary-agreement modelling.
Introducing SyMAP MFN
Bringing GENEROUS, GLOBE and GUARD into one portfolio modelling workflow.
Put the policy into your portfolio
What could MFN mean
for your pricing strategy?
Use SyMAP MFN to compare policy scenarios, model rebate and revenue effects, and explore manufacturer agreement assumptions alongside global pricing decisions.
Updated GLOBE modelling: Assess rebate and revenue effects under the GLOBE final rule, then test how a hypothetical extension could change the outlook. Watch the GLOBE walkthrough →
01Compare CMS, voluntary and baseline paths
02Explore price and launch assumptions
03Connect policy exposure to revenue
Prefer an expert-led project? View projects →A few useful distinctions
MFN, explained.
Clear answers to common policy and modelling questions.
What does most-favored-nation pricing mean?
MFN is an approach that links a US drug price or rebate calculation to prices in other countries. The term does not describe a single universal formula. Reference baskets, price measures and covered products depend on the pathway.
Are GLOBE and GUARD already in effect?
Not yet. GLOBE has a final rule, published on 2 October 2026 and scheduled to take effect on 30 November; the model is scheduled to begin on 1 January 2027 and its first performance year on 1 April 2027. PhRMA challenged the rule on 7 October. No order pausing the model was identified in public sources checked on 10 October. Follow the case. GUARD remains a proposal: its final rule was still under OMB review at the 10 October check. Distinguish both from GENEROUS and announced manufacturer agreements.
Are manufacturer agreements the same as GENEROUS?
No. Agreements can include wider commitments, while GENEROUS provides a Medicaid model. They can overlap: Merck discloses an MFN agreement and participation in GENEROUS. Model the interaction rather than simply adding two exposures.
Does every manufacturer agreement have the same duration?
No single duration should be assumed. Merck discloses a three-year agreement with exceptions for certain products. Use the relevant company disclosure and distinguish the agreement term from any continuing product obligations.
How does MFN relate to international reference pricing?
International reference pricing uses prices in other countries to inform domestic pricing decisions. MFN extends that connection to US pricing through different policy and agreement mechanisms. A change in one market can therefore matter to a wider pricing strategy.
Can these tools calculate my portfolio’s MFN liability?
These tools explain and compare pathways. A portfolio assessment needs product eligibility, pricing inputs, volumes, agreement terms and explicit policy assumptions. Explore modelling in SyMAP MFN.
Sources & policy context
Sources behind this update
Recent developments link to their dated sources in the update archive above. Programme summaries distinguish agency proposals, announcements, legal challenges and company disclosures. The post-deadline GENEROUS participation count is attributed to Inside Health Policy; CMS’s public model page still shows the earlier application update. Historical analysis is linked separately above. About Symaptics and our pricing expertise.